Regal Assets Analytics

Bill Langbein

FDA Approves Biocryst (BCRX) Drug For HAE; Sanacurrents Closing Out Coverage

By |2020-12-07T11:59:13-05:00December 7th, 2020|Categories: Bill Langbein, SanaCurrents, SanaCurrents Updates|Tags: |

After the markets closed on Thursday, December 3, BioCryst Pharmaceuticals [...]

Read More
 0

Keeping an Eye on ALLO, SYRS, PTGX, AUTL, and IMRA in Light of Biotech Catalysts; Disclosure Updates

By |2020-12-07T11:59:23-05:00December 7th, 2020|Categories: Bill Langbein, SanaCurrents, SanaCurrents Updates|Tags: , , , , |

Clinical data findings related to five SanaCurrents catalysts will be [...]

Read More
 0

Xenon Pharmaceuticals (XENE) Probability Sentiment

By |2020-12-07T10:42:27-05:00December 6th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: |

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Probability Sentiment [...]

Read More
 0

SanaCurrents holding BioCryst (BCRX) shares into December 3 PDUFA

By |2020-12-02T10:26:29-05:00December 2nd, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|Tags: |

The FDA will decide on December 3 whether to approve [...]

Read More
 0